Evogene Ltd.

Earnings Release • Feb 1, 2021

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2021

Commission File Number: 001-36187

EVOGENE LTD.

(Translation of Registrant's Name into English)

13 Gad Feinstein Street Park Rehovot P.O.B 2100 Rehovot 7612002 Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

CONTENTS

Attached hereto and incorporated by reference herein is the following exhibit:

99.1 Evogene Investor Presentation – February 2021.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

EVOGENE LTD.(Registrant)

Date: February 1, 2021

By: /s/ Dorit Kreiner

——————————————

Dorit Kreiner Chief Financial Officer

3

EXHIBIT INDEX

EXHIBIT NO. DESCRIPTION 99.1Evogene Investor Presentation –February 2021.

Exhibit 99.1

Forward Looking Statement

This presentation contains "forward-looking to future events, and we may from time to time make other statements, regarding our outlook or expectations for financial or operating results and/or other maters regarding or affecting Evogene Ltd. or its subsidiaries (collectively, "Evogene" of "We"), that are considered "forward-looking statements" as defined intigation Reform Act of 1995 (the "PSLR4") and other securities laws. Such forward-looking statements nay be use of such words as "believe," "should" "planned." "should" "planned." "intend" and "potential" or words of similar meaning. For example in this presentation when it discusses its near-term value drivers, including statements to the effect hat it will reach commercialization, regulatory agreements; its milestones for each of 2021 and 2022; its belief that its diverse portfolio with each individual opportunity within its portfolio and in its product pipeline; and its estimated cash usage for its year ending December 31, 2020. For these statements, Evogene chams for forward-boking statements contaned in the PSLRA and other securites are based on current expectations, estimates, projections, describe opinions about future events, involve certaintes which are difficult to predict and are not quarantees of future performance. Therefore, actual future results, performance or active of Evogene may differ materially from what is expessed or implied by such forward-hoking statements due to a variety of factors, many of which are beyond Evogene's control, including, without finitation, the global spread of COVID-19, or the Coronavirus, the various deriving the extent of Evogene continuing to maintain its holdings in its subsidiary companies, whether Evogene is able to comply with requirements, the dearee of Evogene's success at adapting to the continuous technological changes in its industries, and those factors and risks described in Evogene's Annual Report on Form 20-F and in other reports it files and furnishes with the U.S. Securities and Exchange Commission (the "SEC") and the In addition, Evogene relies, and expects to continue to rely, on third parties to conduct certain as its field-trials and pre-clinical studies, and if these third parties do not successfuly cary out their contractual duties, comply with regulator required deadlines (including as a result of the effect of the Coronavirus), Evogene may experience significant delays in the conduct of its and oral forward-looking statements attributable to us or persons acting on our behalf are expressy qualified in their entrety by the previous statements. Exclose information as required by applicable securites laws, Evogene disclaims any obligation or commitment to uptained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other of constitute or form part of any invitation or offer o sell, or any solicitation of any invitation or offer to purches of Evogene or any other entity, nor shall the information or any part of it or the fact of its distribution form the basis of or be relied on in connect, commitment or relaing thereto or to the securities of Evogene.

The trademarks included herein are the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of Evogene.

evogene

Agenda

* Introduction Fields of activity Summary

Annex I - Technology

Annex II - Financial Fundamentals

OUR VISION

Revolutionizing life-science product discovery & development, utilizing cutting edge computational biology technologies.

DECODING BIOLOGY

evøgene

Life-science product discovery & development challenges

High cost, long time-to-market and low probability of success

The opportunity

Utilize comprehensive and integrated computational biology to substantially increase the probability of success, while reducing the time and cost of life-science product discovery & development.

When biology meets disruptive technologies; introducing-

Incorporating deep scientific understandings together with big data and advanced artificial intelligence technologies (AI), seeking to successfully discover & develop novel lifescience based products.

Developed over two decades at an investment of tens of millions of dollars and validated through collaborations with industrial leaders & internal results

evogene

Tailor-made Engines for product discovery & development

The CPB platform enhances product discovery and development through dedicated Engines for products based on three core components:

• · Microbes
• · Small molecules
• · Genetic elements

evogene

Tailor-made Engines for product development

+ Discovery

Computational selection of the most promising candidates to initiate the product development process.

+ Development

Computational driven solution addressing optimization development challenges for the selected candidates, without impairing its ability to address other product attributes, supporting the way to successful commercialization.

evogene

A first version of our artificial intelligence-driven platform was successfully designed for hundreds of unique gRMAs for 5 different genomes, applicable in pharma, agriculture and aquaculture

Evogene Provides 2020 Year-End Update for CRISPR-II Consortium

Progress includes completion of a first version of the artificial intelligence-driven platform for genome-editing

Rehovot, Israel - January 5, 2021 - Evogene Ltd. (NASDAQ: EVGN), (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product development across several market segments, provided today a year-end update for the CRISPR-IL consortium, of which it is a member and Evogene's CSO, Dr. Eyal Emmanuel, serves as the consortium's Chairman. The CRISPR-IL consortium, which is supported by the Israeli Innovation Authority, was established to develop an artificial intelligence-based system, for CRISPR-CAS based workflows, "Go-Genome", providing end-to-end genome-editing, with improved precision and efficiency.

evogene

Product development through collaborations

Joint development with leading companies for defined products utilizing Evogene's unique solution. Later-stage development and commercialization of the product will likely be done by the partner.

Potential revenue for Evogene

• · Licensing and research payments
• · Milestone payments
• · Revenue sharing

Main Business Model Until 2014:

GMO seed traits for yield and abiotic stress for wheat

• · GMO seed traits for yield and abiotic stress for corn
• · GMO seed traits for ASR resistance for soybean
• MONSANTO & syngenta
• · GMO seed traits for yield · · GMO seed traits for and abiotic stress for corn and soybean

· GMO (2013) and genome

editing (2019) seed traits for fusarium resistance

nematode resistance

evøgene

evogene

Product development through subsidiaries

Establish independent entities focusing on a defined commercial field with an exclusive license to use Evogene's unique solutions for product development. The subsidiary may develop and commercialize products independently or through strategic collaborations.

Potential revenue for Evogene

• · Licensing and research payments
• · Consolidated revenues
• · Dividends (subject to profits generated by subsidiary)

Main Business Model from 2015:

BIOMICA Microbiome based therapeutics

casterra Ag-solutions for castor

Agenda

* Introduction

Fields of activity

Summary

Annex I - Technology

Annex II - Financial Fundamentals

evøgene

Potential fields of activity

evøgene

Current life-science based products under development

is unuel development
			HUMAN HEALTH	AGRICULTURE	OTHER INDUSTRIES
PB	Micro BoostA	MICROBES	Microbiome based Therapeutics	Ag-Biologicals
	Chem PassA	SMALL MOLECULES	Drugs based on small molecules	Ag-Chemicals
	Gene Rator Al	ELEMENTS GENETIC	Medical Cannabis	Seed Traits	Ag-solutions for castor oil production

evøgene

Development & commercialization through subsidiaries and collaborations

* non-exclusive license

evøgene

*Evogene holdings in its applicable subsidiaries

evogene

Mission:

Discovery and development of novel therapies for microbiome-related human disorders using computational biology,

Product Pipeline:

Immuno-oncology program:

• · Combination therapy for cancer with checkpoint inhibitors
• · Pre-clinical stage
• · Addressable market size expected by 2026* \$243B

GI related disorders:

• · Inflammatory Bowel Disorder (IBD) pre-clinical stage
• · Irritable Bowel Syndrome (IBS) discovery stage
• · Addressable market size expected by 2026: Inflammatory Bowel Disorder - \$22.4B**, Irritable Bowel Syndrome*** - \$3.3B

MDRO:

• · Multi Drug Resistant Organisms (antimicrobial resistance)
• · Clostridium Difficile Infection (CDI) discovery stage
• · Methicillin-resistant Staphylococcus aureus (MRSA)- discovery stage
• · Addressable market size expected by 2026: CDI**** \$1.7B, MRSA**** - \$3.9B
• www.dlobenewswire.com/news-release/2019/07/1884118/0/en/Cancer-Immunotherapy-Market-To-Rescribing-By-2026-Reports-Ind-Data.html
• www.pmewswire.com/news-releases/the-slobal-inflammatory-bowel-diseases-ibd-drop-market-is-estimated-at-6-7th-in-2023-30068523.html
• www.grandviewresearch.com/industry-analysis/irritable-bowel-syndrome-ibs-treatment-market www.globaldata.com/global-clostridium-difficile-infections-market-approach-1-7-hillion-2026/

*** www.pressment.com/enservately-state/splate/de/selectioners/sport/de-color-de-seat-over-of-stillitis-cous-became of endeles-counter-de-seasonality-season-de-seasonalized o

evogene

Expected main near-term value drivers:

2020

• V Extend pre-clinical study in immuno-oncology program.
• V Initiate scale-up and first GMP production of drug candidates in immuno-oncology program.

2021

• · Proof of concept, first in man study, in the immuno-oncology program.
• · Extend pre-clinical study in IBD program.

Example Results:

Immuno-Oncology program - BMC128 potentiate the effect of anti-PD-1 therapy (immunotherapy) in-vivo

Improved antitumor activity in mice following the administration of BMC128, compared to treatment with immunotherapy alone

evogene

Biomica Announces Positive Pre-Clinical Results in its Immuno-Oncology Program

Biomica's, a subsidiary of Evogene Ltd., live biotherapeutic drug candidate BMC128 administered in combination with Immune Checkpoint Inhibitors (ICI) significantly improved anti-tumor activity. Proof-of-concept first-in-man studies expected next year

Rehovot, Israel - September 8, 2020 - Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN), today announced positive pre-clinical in-vivo results in its immuno-oncology program for a follow-on combination of bacterial strains. In these studies, Biomica tested BMC128, which consists of four live bacterial strains derived from Biomica's drug candidates BMC121 and BMC127. Treatment with BMC128, both prior to and in combination with ICI, significantly improved anti-tumor activity in mice.

CANONIC | Medical Cannabis

Mission:

Commercialize precise & stable medical cannabis products for better therapeutic effects using computational biology.

Product Pipeline:

MetaYield Products:

• · Stable enhancement of total plant compounds: · Increased compounds per plant
  • · Increased compounds per area

Total Cannabis market size expected by 2024 - \$42.7B*

Precise Products:

• · Stable enhancement of specific active compounds for pain and inflammation
  • · Medical indication focus
  • · Compound profile focus

Medical Cannabis market size expected by 2024 - \$25.6B*

Expected main near-term value drivers:

2020

• ✔ Conduct pre-clinical studies to support the development of Canonic's medical cannabis products.
• · Demonstrate yield improvement in cannabis lines under development.
• ✓ Engagement with commercial partners for cultivation and production.

2021

• · Pre-commercial activity with first cannabis variety towards commercialization in 2022.
• · Demonstrate clinical effects of Canonic varieties based on dedicated research with a medical institution.

*Source: Arcview Market research/BDS Analytics 2020

evogene

CANONIC | Medical Cannabis

Example Results:

MetaYield products under development - increased compounds per area, addressing the T20/C4 (THC 16%-24% and CBD 0%-7%) market segment, which currently consists of 70% of the Israeli medical cannabis market

Medical Cannabis aiming at high THC, high yield, big inflorescence and dense trichomes

evogene

Canonic Announces Signing of First Cultivation Agreement for its Medical Cannabis Varieties

Recent agreement with Telcann for plant growth services completes major component in production infrastructure for planned product commercialization in Israel in 2022

Rehovot, Israel - December 23, 2020 - Canonic Ltd, a company focused on the development of medical cannabis products and a wholly owned subsidiary of Evogene Ltd. (NASDAQ: EVGN), (TASE: EVGN) announced today that it has signed its first commercial agreement with a licensed medical cannabis cultivator, Telcann Ltd, for the provision of plant growth services in Israel to Canonic. With this agreement, Canonic has completed the establishment of the major component required for the production infrastructure of its medical cannabis products, MetaYield and Precise in Israel. Canonic is expected to proceed with the execution of its commercialization (go-to-market) plan of medical cannabis products in Israel under its own label. Canonic's first product, from its MetaYield program, is aimed to be commercialized commencing in 2022.

Mission:

Design of next-generation effective, sustainable and safer crop protection products by leveraging computational biology and chemistry.

Product Pipeline:

Expected main near-term value drivers:

Herbicides:

• · Novel MoA (Mode-of-Action) selective/non-selective herbicides
• Relevant target crops Cereals, Rice, Corn, Soybean,
  Cotton, Canola, Sugar beet, Other TBD
• · Addressable market size expected by 2022*: \$34B
• · Lead stage

Insecticides:

• · Novel SoA (Site-of-Action)
• Addressable market size expected by 2022 *: \$17B
• · Hit-to-Lead stage

2020

• Sign collaboration based on pre-Lead candidates from herbicide program.
• ✓ Reach a `Lead' in herbicide program.

2021

• · Reach a POC for a herbicide tolerance gene trait, for a `Lead' herbicide in development.
• · Licensing agreement of 'Lead' herbicide candidate.

*https://www.prnewswire.com/news-releases/global-3410-billion-herbicide-markets-300458389.html

evogene

Example Results:

Leading novel MoA herbicide candidate - displaying efficacy in eradicating multiple important weed species in field tests

Field test of APH1 against a panel of grass and broadleaf weeds - untreated control vs APH1

evogene

AgPlenus Announces Reaching a 'Lead' Stage in its Novel Mode-of-Action Herbicide Program

This significant development milestone was achieved following positive results for product candidate APH1 in field tests with commercial level application rates on a broad panel of weeds

Rehovot, Israel - December 15, 2020 - AgPlenus Ltd., an innovative company designing effective, sustainable crop protection products by leveraging computational biology and chemistry, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN), (TASE: EVGN), announced today that it has reached the 'Lead' stage in its novel Mode-of-Action (MoA) herbicide program. The achievement of this milestone follows the conclusion of field tests that demonstrated that product candidate APH1, at commercial dose rates, effectively controlled a broad panel of weeds, including weeds that are known to have resistance to existing herbicides. These results were confirmed in independent field tests conducted by SynTech Research, an agricultural R&D contract research organization located in California.

Mission:

Improve food quality, sustainability and agricultural production of microbione based ag-biological products using computational biology.

Product Pipeline:

Bio-stimulants (live microbials for yield improvement):

• · Spring wheat seed treatment/soil application -
• development stage 2
• · Corn seed treatment pre-development stage
• · Addressable market size * : corn -120M ACRES, spring wheat - 25M ACRES

Bio-pesticides (live microbials for pest protection):

· Mildew, fruit rot for fruit and vegetables (initial focus on grapes) - foliar application - development stage 1

• Seedling disease for corn, soy seed treatment for disease protection- pre-development stage
• Bio-insecticides 1st focus corn (seed treatment), soy (foliar) application for insect protection - pre-development stage
• Addressable market size * : mildew, fruit rot \$550M, seedling diseases - \$500M, bio-insecticides - \$1.5B.

*Company estimation

evogene

Expected main near-term value drivers:

2020

• Advance phase in bio-pesticide.
• √ File for registration of a wheat bio-stimulant product and advance phase.

2021

• · Receive regulatory approval for a wheat bio-stimulant product.
• · Advance a wheat bio-stimulant to pre-commercial activities with early-adopter farmers.

Example of treatment with LAV312 against Botrytis Cinerea in vines - untreated control vs treated vines

Lavie Bio Announces Positive Results for LAV311 and LAV312 in its Bio-Fungicide Program

Positive results were achieved in a series of vineyard trials for bunch rot diseases conducted in Europe and the United States

Rehovot, Israel - October 29, 2020 - Lavie Bio Ltd. (Lavie Bio), a leading ag-biologicals company focusing on improving food quality, sustainability and agriculture productivity through the introduction of microbiome based products, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), announced today positive trial results for two of its leading bio-fungicide product candidates. The successful results for LAV311 and LAV312, targeting bunch rot diseases, mark the advancement of these candidates to "Development Stage 2" [1] These vineyard trials, conducted in target locations in Europe and the U.S., resulted in significantly better efficacy and consistency than existing comparable commercial biological benchmarks, and competitive to commercial chemical benchmarks, both tested as part of these trials. The positive results will support Lavie Bio's current plan to launch its first biofungicide product for controlling bunch rots for use in fruit and vegetables in 2024.

Lavie Bio's wheat field in the USA during harvest

Lavie Bio Provides Product Pipeline Update for 2020

LAV211 bio-stimulant advancing towards anticipated 2022 commercial launch in spring wheat; Product advancement achieved in multiple programs

Rehovot, Israel - December 29, 2020 - Lavie Bio Ltd. (Lavie Bio), a leading ag-biologicals company focusing on improving food quality, sustainability and agriculture productivity through the introduction of microbiome-based products, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), has announced an update on certain advancements achieved in its pipeline in 2020, including phase advancement of bio-stimulant LAV211, towards an anticipated commercial launch in 2022.

evogene

Subsidiaries - expected main near-term value drivers

(as presented at the beginning of 2020)

	2020		2021	2022
BIOMICA	Extend pre-clinical study in immuno- oncology program	Initiate first GMP production of drug candidates in immuno- oncology program	Extend pre-clinical study in Inflammatory Bowel Disease (IBD) program	Proof of concept, first in man study, in the immuno-oncology program
CANONIC	Engagement with commercial partners for cultivation and production	Demonstrate yield ımprovement in cannabis lines under development	Pre-commercial activity towards commercialization in 2022	Demonstrate clinical effects of a developed line, based on dedicated research with a medical institution
"agPlenus	Sign collaboration based on pre-Lead candidates from herbicide program	Reach a 'Lead' in herbicide program	Reach a POC for a herbicide tolerance gene trait, for a `Lead herbicide in development	Licensing agreement of 'Lead' herbicide candidate
lavie bio	Advance phase in bio-pesticide	File for regulatory approval for a wheat bio-stimulant product & advance phase	Receive regulatory approval for a wheat bio-stimulant product	Advance a wheat bio- stimulant product to pre- commercial activities with early-adopter farmers
Pipeline Regulation Product Launch Collaboration * Additional milestone on slide 20
evogene DECODING BIOLOGY * 26

Agenda

* Introduction - Fields of activity

Summary

Annex I - Technology

Annex II - Financial Fundamentals

evøgene

Summary

Our mission-Improvement of life-science product development utilizing cutting edge computational biology technologies

CPB platform - a unique technology platform stemming from the incorporation of deep scientific understandings of biology together with big-data and artificial intelligence technologies

Evogene's three unique engines target to improve the development of products based on the following core components:

• 1. MicroBoost AI for products based on microbes
• 1. ChemPass AI for products based on small molecules
• 1. GeneRator AI for products based on genetic elements

Dual based business model - utilizing Evogene's solutions for:

• 1. Product development through collaborations
• 1. Product development through subsidiaries

Four main market-oriented subsidiaries, each with a clear milestone roadmap:

• 1. Biomica human-microbiome based therapeutics
• 1. Canonic medical cannabis
• 1. AgPlenus ag-chemicals
• 1. Lavie Bio ag-biologicals

Key shareholder since September, 2020 ARK Investment Management LLC holding ~13%*

Significant catalysts expected in the next 12 months towards 2022 product commercialization & strategic collaborations

*Based on a schedule 13G filed by Ark with the SEC on October 9, 2020

evogene

THANK YOU!

Annex I: Technology

evøgene

evøgene

The challenge in creating life-science based products

Common practice

Discovery - selection of product candidates mainly addressing efficacy

Candidate Selection

Efficacy

Safety

Selectivity

Shelf-life

Other

evøgene

DECODING BIOLOGY * 32

Product

Launch

The challenge in creating life-science based products

Common practice

Discovery - selection of product candidates mainly addressing efficacy

Development - inefficient optimization & difficulty in addressing a single challenge without impairing others

X Low probability of success

X Long time to market

X High development costs

Product Definition

Candidate Efficacy Selection

Safety

Selectivity

Shelf-life

Product

Launch

10

evogene

DECODING BIOLOGY * 33

X

Other

evogene

Evogene's AI-based solution: Development

A multi-attribute computational analysis, addressing a specific development challenge of the selected candidate, without impairing its ability to address other product attributes.

evogene

Evogene's AI engines provide tailor-made solutions

+ Discovery

Computational prediction of candidates, to serve as the product's core-component, addressing multiple key product attributes.

+ Development

Computational driven solution for guiding and assessing the optimization process of the selected core component, without impairing other key product attributes.

ം Micro BoostAl Chem Gene RatorAl DECODING BIOLOGY * 36

evolgene

Annex II: Financial Fundamentals

evøgene

Key Financials: Balance Sheet

Thousands of US \$	30.09.2020	31.12.2019
Current Assets	45,392	49,027
Long-Term Assets	20,593	22,337
Total Assets	65,985	71,364
Current Liabilities	4,639	5,746
Long-Term Liabilities	5,276	5,401
Equity attributable to equity holders of the Company	44,930	50,144
Non-controlling interest	11,140	10,073
Total Liabilities & Shareholders Equity	65,985	71,364

Key Points:

• · Consolidated cash position: ~\$43.5 million as of 30.09.2020
• · No bank debt
• · Estimated net cash usage for 2020 (without Lavie Bio): \$13-\$15 million
• · Listed on TASE (2007) and NASDAQ (2013)

evøgene